Lithium  administered as Lithium  carbonate is frequently used as a mood stabiliser in the treatment of bipolar  disorder (manic depression).  It acts by  enhancing reuptake of neurotransmitters thereby reducing their concentration in  the neuronal junction; the result is a sedating effect on the central nervous  system.   Due to its narrow therapeutic and toxic range,  it is important to monitor lithium levels in the serum to avoid toxicity,  optimise therapeutic effect and ensure compliance.

The new and  improved Lithium kit from Randox is intended for the quantitative in vitro determination of Lithium in serum and is suitable for use on a wide range of  clinical analysers.  

The new  reagent is liquid stable for ease of use and offers an improved open vial stability  of 14 days at 10°C.  Other  features include a wide measuring range of 0.281-3.00 mmol/L, excellent precision,  traceability to the NIST reference method and limited interference from  Bilirubin, Triglycerides and Haemoglobin.  

Randox provide a wide range of other tests for monitoring the use of drugs  with very small therapeutic ranges.   Tests include; Digoxin, Gentamicin, Phenytoin, Theophylline, Valproic  acid, Phenobarbital and Carbamazepine.  

In addition to this Randox can also provide therapeutic  drug quality controls.  Our therapeutic  drug controls are 100% human in origin and contain a comprehensive menu of 18  analytes with accurately assigned method specific target values and ranges  quoted for the most common instruments and methods.